Good manufacturing practices for pharmaceutical products

In short: Good manufacturing practices (GMP) are the controls that help ensure medicines are consistently made and checked against the quality requirements for their intended use. This overview is for pharmaceutical production, quality assurance and quality control staff, as well as students. GMP depends on a functioning quality system across people, premises, equipment, materials, records, production and testing—not on final-product testing alone.

What are good manufacturing practices?

GMP is the part of quality management concerned with making and controlling medicines consistently against the standards for their intended use and applicable product requirements. It applies to both production and quality control. The purpose is to manage risks in manufacture that cannot be reliably addressed by testing finished batches alone, including contamination, mix-ups and failures to follow the approved process.

GMP is implemented through a pharmaceutical quality system (PQS). Senior management is responsible for ensuring that the system is established, resourced and understood across the organisation. Production, quality control, quality assurance, engineering, stores and other relevant functions each have defined responsibilities within it.

Core elements of a GMP system

People and training

Personnel need suitable qualifications, experience and training for their assigned work. Responsibilities and reporting lines should be clear. Training should cover the procedures relevant to each role and be recorded so that the organisation can demonstrate who was trained and when.

Premises, equipment and materials

Facilities and equipment should be suitable for their intended operations, maintained in a controlled state and arranged to support orderly work and prevent mix-ups or contamination. Materials and products should be identified and handled according to documented controls throughout receipt, storage, sampling, processing and dispatch.

Documented processes and records

Manufacturing and control activities should follow approved instructions written for the actual process and facility. Records made during the work provide evidence that required steps were completed and allow the history of a batch to be reconstructed. Records should be clear, complete and retrievable for review.

When an activity does not follow the approved process, the event should be recorded, assessed and investigated at a level appropriate to its potential effect on product quality. Corrective and preventive actions should address the cause and have their effectiveness evaluated.

Qualification, validation and change management

Qualification provides documented evidence that facilities, utilities and equipment are suitable for their intended use. Validation provides evidence that a process or procedure can achieve its intended result consistently. The scope and extent of these activities should be justified and controlled within the quality system.

Planned changes should be assessed and approved before implementation, including consideration of their potential effect on product quality and any required regulatory action. After implementation, the organisation should confirm that the intended outcome was achieved and that no unintended quality impact occurred.

Quality control, release and product monitoring

Quality control includes sampling, specifications, testing, documentation and review. Test results are one part of the evidence used to assess a batch; they do not replace control of the manufacturing process or review of the batch records. A batch should be released only through the authorised process after the required manufacturing and control records have been reviewed.

Ongoing product quality review, complaint handling, deviation investigations and stability monitoring help identify trends or recurring problems. A recall system should make it possible to act when a product quality issue requires removal of affected product from the supply chain.

Applying GMP in India

WHO guidance provides internationally used GMP principles, while legal requirements depend on the jurisdiction and product. In India, manufacturers should consult the applicable Drugs Rules, including Schedule M, and the current official notifications, amendments and corrigenda relevant to their products and operations.

CDSCO lists the revised Schedule M notification as G.S.R. 922(E), dated 28 December 2023, and also lists a corrigendum dated 25 October 2024. The notification record and later notices should be checked directly when determining the requirements and implementation timeline that apply to a particular manufacturer. Do not rely on an older summary or a general article for a compliance date.

GMP and finished-product testing

Finished-product testing confirms selected characteristics of the sample tested against its specification. It cannot by itself establish that every unit in a batch was made under controlled conditions. GMP therefore combines defined processes, suitable facilities and equipment, trained personnel, controlled materials, complete records, in-process controls and quality-unit review.

Frequently asked questions

What is the main purpose of GMP?

GMP helps ensure medicines are consistently produced and controlled to the quality requirements for their intended use, while managing risks that could affect product quality.

Does passing finished-product tests prove that a batch complied with GMP?

No. Test results are important, but they do not replace evidence that the process was controlled, records were complete, deviations were assessed and the batch was reviewed through the authorised quality system.

Is WHO GMP guidance the same as Indian law?

No. WHO publishes guidance. Manufacturers in India must determine their obligations from the applicable Indian laws and current official notifications, including relevant Schedule M requirements.

What is revised Schedule M?

It is the revised GMP schedule notified under the Drugs Rules, 1945. CDSCO’s notification index identifies G.S.R. 922(E) dated 28 December 2023 and a corrigendum dated 25 October 2024. Check the official records for later changes and applicability details.

Who is responsible for GMP?

GMP requires participation across the organisation. Senior management provides leadership and resources, while departments and individuals carry out the responsibilities assigned to them in the pharmaceutical quality system.

References

• World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series No. 986, Annex 2, 2014. Official publication page; official Annex 2 PDF.
• Central Drugs Standard Control Organization, Government of India. G.S.R. 922(E): Notification of Schedule M of the Drugs Rules, 1945, 28 December 2023; corrigendum, 25 October 2024. CDSCO Gazette Notifications.
• Central Drugs Standard Control Organization, Government of India. Circular: Implementation of Schedule M and WHO Technical Report Series (TRS), File No. QMS/38/Misc/2024, 7 August 2024. Official circular.